Impact of Clinical Pharmacist-Led Collaborative Drug Therapy Management on Hospitalization Rates and Healthcare Costs Among Patients with Heart Failure
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background: Heart failure (HF) is a prevalent chronic condition associated with substantial clinical and economic burdens. Collaborative Drug Therapy Management (CDTM) involving clinical pharmacists has emerged as a promising model to optimize therapeutic outcomes. Objective: To evaluate the effect of pharmacist-led CDTM interventions on hospitalization rates and healthcare utilization among patients with heart failure. Methods: In this prospective cohort study conducted at King Fahad Medical City, 592 adult patients with left ventricular systolic dysfunction received pharmacist-directed care between January 2023 and January 2025. Clinical pharmacists optimized pharmacotherapy, monitored labs, and provided patient counseling. Hospitalization and emergency department (ED) visits were recorded over 6 months before and after the intervention. Paired t-tests were used to compare pre- and post-intervention outcomes. Results: A total of 1,392 interventions were performed (mean: 2.4 per patient), with an acceptance rate of 86%. Hospitalizations significantly decreased from 0.79 to 0.24 per patient post-intervention (p = 0.001). Common interventions included medication initiation (29.8%), dose adjustments, and diabetes management. Individualized education was provided to patients with poor adherence (34.5%). Conclusion: This study demonstrates that clinical pharmacist-led collaborative drug therapy management (CDTM) significantly improves heart failure care by reducing hospitalization rates, optimizing medication use, and enhancing adherence to guideline-directed therapy. These improvements were driven by pharmacists’ roles in proactive medication management, adverse event monitoring, and patient education. To expand these benefits, especially in low- and middle-income regions such as the Middle East, systemic barriers—such as regulatory constraints and limited interprofessional collaboration—must be addressed.